continues to work with Congress, federal agencies, and other stakeholders to
ensure continued access to safe and effective hematologic drugs.
has asked the manufacturer of the leukemia chemotherapy drug Iclusig
(ponatinib) to suspend marketing and sales of Iclusig because of the risk
of life-threatening blood clots and severe narrowing of blood vessels.
Patients currently receiving Iclusig should discuss with their health care
professionals the risks and benefits of continuing treatment with the
drug. The drug manufacturer, Ariad Pharmaceuticals, has agreed to FDA's
request to suspend marketing and sales of Iclusig while the FDA continues
to evaluate the safety of the drug.